Follow us on:

Linkedin Facebook

Nuformix hosting online Q&A session on 13 June 2023

Nuformix plc

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30 p.m. GMT on Tuesday 13 June 2023.  This session is open to all existing and prospective shareholders.  Those who wish to attend should register via the following link where they will be provided with access details:

https://us02web.zoom.us/webinar/register/WN_fV_2UztcQLSl1S1tC4vTGg

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: [email protected]

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Nuformix plc

Nuformix advances NXP002 programme with £168,750 Placing

Nuformix plc (LON:NFX) raises £168,750 for fibrosis drug development through a new share placing, advancing its NXP002 programme and corporate goals.
Nuformix plc

Nuformix plc Annual Results for the period ended 30 September 2024

Nuformix plc (LON:NFX) targets unmet needs in fibrosis and oncology via drug repurposing, focusing on partnering its NXP002 lead program for IPF and PPF.
Nuformix plc

Nuformix submits NXP002 Orphan Drug Designation Application to EMA

Nuformix plc (LON:NFX) advances NXP002 for Idiopathic Pulmonary Fibrosis, applying for Orphan Drug Designation with European Medicines Agency.
Nuformix plc

Nuformix submits NXP002 Orphan Drug Designation draft application

Nuformix plc targets fibrosis and oncology needs through drug repurposing, submitting a draft for EMA Orphan Drug Designation for NXP002 in IPF.
Nuformix plc

Nuformix Executive Director discusses patent updates, interim results and future plans (LON:NFX)

Nuformix plc (LON:NFX) Executive Director Dr. Dan Gooding reveals insights on new patents for NXP002 & NXP004, interim results, and future plans in an exclusive interview.

Nuformix Secures Key Patents and Outlines Future Plans for NXP002 and NXP004 (VIDEO)

Nuformix Plc provides a patent update for its NXP002 and NXP004 programs in fibrosis and oncology. Learn more in this interview with Executive Director Dr. Dan Gooding.

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.